MelanomaPhase 2NCT01092728
Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma
A Phase 2 study testing Dasatinib and Surgical Resection in people with Melanoma, run by M.D. Anderson Cancer Center at 1 site in United States.
Trial summary
The goal of this clinical research study is to compare how the drug Sprycel (dasatinib) can help to control the tumor in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma. The safety of this drug will also be studied. Objectives: Primary Objectives: 1. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Melanoma
- What is being tested?
- Dasatinib and Surgical Resection
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 19 participants
- Where
- 1 siteUnited States
- Study dates
- Mar 2011to Aug 2014
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients must have primary, recurrent or metastatic melanoma with one of the following pathology or characteristics: i) acral lentiginous melanoma ii) mucosal melanoma iii) any known KIT mutation.
- (Continued 1) If 20 patients without tumors harboring exon 11 or 13 KIT mutation are enrolled and treated before the completion of the patient accrual of 30, only those with tumors harboring exon 11 or 13 KIT mutation will be enrolled. Likewise, if 10 patients with tumors harboring exon 11 or 13 KIT mutation are enrolled and treated before the completion of the patient accrual of 30, only those without tumors harboring exon 11 or 13 KIT mutation will then be enrolled.
- Patients must have measurable disease by 18-Fluoro-deoxyglucose positron emission tomography (FDG-PET) (with or without computed tomography (CT)) defined as having a maximum standardized uptake value (SUVmax) of 3 and SUVmax ofat least 2 fold greater than background.
- Patients scheduled for FDG-PET should have uptake of the tracer in at least one lesion (tumor-to-muscle ratio >2) in the baseline PET/CT scan in order to be eligible for the follow-up FDG PET scans.
- Patient must have surgically resectable melanoma lesion(s) or biopsiable lesion(s) which are amenable to 2 separate biopsy procedures by a core needle or excision.
- Age >/= 18 years.
Show all 12Show fewer
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
- Adequate Organ Function: a. Total bilirubin < 2.0 times the institutional Upper Limit of Normal (ULN), b.Hepatic enzymes (aspartate transaminase, alanine transaminase (AST, ALT) ) </= 2.5 times the institutional ULN, c. Serum Creatinine < 1.5 time the institutional ULN, d.Neutrophil count >/= 1500; Platelets >/= 75,000;
- Ability to take oral medication (dasatinib must be swallowed whole)
- Concomitant Medications: a. Patient agrees to discontinue St. Johns Wort while receiving dasatinib therapy (discontinue St. Johns Wort at least 5 days before starting dasatinib), b.Patient agrees that IV bisphosphonates will be withheld for the first 8 weeks of dasatinib therapy due to risk of hypocalcemia.
- Women of childbearing potential (WOCBP) must have: a) A negative serum or urine pregnancy test (sensitivity 25 IU human chorionic gonadotropin (HCG/L) within 72 hours prior to the start of study drug administration b) Persons of reproductive potential must agree to use and utilize an adequate method of contraception throughout treatment and for at least 4 weeks after study drug is stopped. Prior to study enrollment, women of childbearing potential must be advised of the importance of avoiding pregnancy during trial participation and the potential risk factors for an unintentional pregnancy.
- Signed written informed consent including a Health Insurance Portability and Accountability Act (HIPAA) form according to institutional guidelines
Who cannot join
- No other malignancy which required radiotherapy or systemic treatment within the past 5 years.
- Concurrent medical condition which may increase the risk of toxicity, including: a. Pleural or pericardial effusion of any grade.
- Cardiac Symptoms; any of the following should be considered for exclusion: a. Uncontrolled angina, congestive heart failure or MI within (6 months), b. Diagnosed congenital long QT syndrome, c. Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de pointes), d. Prolonged corrected QT interval (QTc) interval on pre-entry electrocardiogram (> 480 msec) [or > 500 msec for patients with a bundle branch block]), e. Subjects with hypokalemia or hypomagnesemia if it cannot be corrected prior to dasatinib administration.
- History of significant bleeding disorder unrelated to cancer, including: a. Diagnosed congenital bleeding disorders (e.g., von Willebrand's disease), b. Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies), c. Ongoing or recent (</= 3 months) significant gastrointestinal bleeding.
- Concomitant Medications, any of the following should be considered for exclusion: a. Category I drugs that are generally accepted to have a risk of causing Torsades de Pointes including: (Patients must discontinue drug 7 days prior to starting dasatinib), I. quinidine, procainamide, disopyramide, II. amiodarone, sotalol, ibutilide, dofetilide, III. erythromycin, clarithromycin, IV. chlorpromazine, haloperidol, mesoridazine, thioridazine, pimozide V. cisapride, bepridil, droperidol, methadone, arsenic, chloroquine, domperidone, halofantrine, levomethadyl, pentamidine, sparfloxacin, lidoflazine.
- Women who: a. are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for at least 4 weeks after cessation of study drug, or, b. have a positive pregnancy test at baseline, or, c. are pregnant or breastfeeding,
Show all 10Show fewer
- Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious) illness
- No active, untreated brain metastases. Patients with known brain metastases will be included if the brain metastases have been treated and stable for at least 3 months without the use of steroid
- HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with dasatinib. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated.
- Patients with melanoma harboring BRAF mutation. If BRAF mutation is not known at the time of screening, patients will still be eligible
Trial locations and contacts
1 site in 1 country.
United States1 site
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030
About this study
Official title: A Phase II Study of Biological Response to Dasatinib Treatment in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma
The goal of this clinical research study is to compare how the drug Sprycel (dasatinib) can help to control the tumor in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma. The safety of this drug will also be studied.
Objectives:
Read more
Primary Objectives:
- To compare the biological response of tumors With and Without Resectable Tumors from patients with acral, or mucosal melanomas after treatment with dasatinib.
Secondary Objectives:
- To assess the safety and tolerability of dasatinib in this patient population Completely Resectable Acral, Chronic Sun-damaged (CSD), and Mucosal Melanoma:
- To assess the median time to recurrence and overall survival of patients with completely resectable acral, CSD, and mucosal melanoma treated with dasatinib
- To assess whether FDG-avidity and KIT phosphorylation responses after treatment with dasatinib predicts prolonged time to recurrence and/or overall survival in patients with completely resectable acral, CSD, and mucosal melanomas Not Completely Resectable Acral, CSD, and Mucosal Melanoma:
- To assess the response rate, progression free survival, and overall survival of patients with acral, CSD, and mucosal melanoma treated with dasatinib
- To assess whether FDG-avidity and KIT phosphorylation responses after treatment with dasatinib predicts response rate, progression free survival, and/or overall survival in patients with acral, CSD, and mucosal melanomas
Read the detailed description
The Study Drug:
Dasatinib is designed to change the function of genes. By changing the function of these genes, it may prevent cancer from growing and spreading.
Study Groups:
If you are found to be eligible to take part in this study, you will be placed into one of two groups depending on if the disease can be removed by surgery on or not. Group 1 will be patients who have melanoma that can be removed by surgery. Group 2 will be patients who have melanoma that cannot be completely removed by surgery.
Study Drug Administration:
For this study, every 4 weeks is a study "cycle."
Dasatinib pills will be taken by mouth with a full glass (8 ounces) of water with or without a meal. The pills should not be crushed or cut, they should be swallowed whole.
If you are in Group 1, you will take 2 dasatinib pills 1 time every day, for 7 days before your already-scheduled surgery. About 6 weeks after surgery (depending on how long it takes you to recover) you will begin taking 2 dasatinib pills 1 time every day for up to 13 cycles as long as you tolerate it and the disease does not come back.
If you are in Group 2, you will take 2 dasatinib pills 1 time every day, for 7 days before your already-scheduled biopsy on Day 8 (+/1 business day) of Cycle 1. Within 5 days after the biopsy, you will begin taking 2 dasatinib pills 1 time every day for up to 13 cycles, as long as you tolerate it and the disease does not come back.
Both groups will be given a pill chart to fill out at home to record when you take the study drug, and how many pills you take each time. You will need to bring the pill chart to every study visit for the study doctor to review. You will also need to bring the pill bottles to each study visit.
Group 1 Study Visits:
After the screening tests have been complete, and before you start taking the study drug, the following procedures will be performed:
- Your weight and vital signs will be measured.
- You will be asked about any drugs you may be taking.
- Your performance status will be recorded.
After 7 days of taking the study drug, and before surgery, the following procedures will be performed:
- You will have a physical exam, including a measurement of your weight and vital signs.
- Blood (about 1 tablespoon) will be drawn for routine tests.
- Your performance status will be recorded.
- You will be asked about any other drugs you may be taking.
- You will have an ECG to check your heart function.
- You will have a PET scan to check the status of the disease.
About 6 weeks after surgery, when you begin taking the study drug on Cycle 1, the following tests and procedures will be performed on Day 1 of each cycle:
- Blood (about 1 tablespoon) will be drawn for routine tests.
- You will have a physical exam, including a measurement of your weight and vital signs.
- Your performance status will be recorded.
- You will be asked about any other drugs you may be taking, and any side effects you may be experiencing.
On Day 15 of Cycle 1 only, the following tests and procedures will be performed:
- Blood (about 1 tablespoon) will be drawn for routine tests.
- You will have a physical exam, including a measurement of your weight and vital signs.
- Your performance status will be recorded.
- You will be asked about any other drugs you may be taking, and any side effects you may be experiencing.
Every 12 weeks while you are receiving treatment, the following tests and procedures will be performed:
- An ECG will be performed to check your heart function.
- You will have a CT scan or MRI scan of the chest, abdomen, and pelvis to check the status of the disease.
Group 2 Study Visits:
After the screening tests have been complete, and before you start taking the study drug, the following procedures will be performed:
- You will have a measurement of your vital signs including your weight.
- You will be asked about any drugs you may be taking.
- Your performance status will be recorded.
After 7 days of taking the study drug, and before the biopsy, the following procedures will be performed:
- You will have a physical exam, including a measurement of your weight and vital signs.
- Blood (about 1 tablespoon) will be drawn for routine tests.
- Your performance status will be recorded.
- You will be asked about any other drugs you may be taking.
- You will have an ECG to check your heart function.
- You will have a PET scan to check the status of the disease.
About 5 days after the biopsy, you will begin taking the study drug again for 3 more weeks to complete Cycle 1. On Day 15 of Cycle 1 only, the following tests and procedures will be performed:
- Blood (about 1 tablespoon) will be drawn for routine tests.
- You will have a physical exam including a measurement of your weight and vital signs.
- Your performance status will be recorded.
- You will be asked about any other drugs you may be taking, and any side effects you may be experiencing.
The following tests and procedures will be performed on Day 1 of each cycle starting with Cycle 2:
- Blood (about 1 tablespoon) will be drawn for routine tests.
- You will have a physical exam, including a measurement of your weight and vital signs.
- Your performance status will be recorded.
- You will be asked about any other drugs you may be taking, and any side effects you may be experiencing.
Every 12 weeks while you are receiving treatment, the following tests and procedures will be performed:
- An ECG will be performed to check your heart function.
- You will have a CT scan or MRI scan of the chest, abdomen, and pelvis to check on the status of the disease.
Length of Study:
You will continue to take the study drug for up to 13 cycles. You will be taken off study early if you experience intolerable side effects, the disease returns (Group 1 only), the disease gets worse (Group 2 only), or if the study doctor thinks it is in your best interest.
If you are in Group 2, and you are benefiting from the treatment, you may be allowed to continue to receive treatment with the study drug after you have completed the 12 study cycles. The study doctor will discuss this option with you in more detail.
End-of-Study Visit:
Within 30 days after the last dose of study drug, you will have an end-of-study visit, at which the following tests and procedures will be performed:
- Blood (about 1 tablespoon) will be drawn for routine tests.
- An ECG will be performed to check your heart function.
- You will have a CT scan or MRI scan of your chest, abdomen, and pelvis performed to check the status of the disease.
- You will have a physical exam, including a measurement of your weight and vital signs.
- Your performance status will be recorded.
- You will be asked about any other drugs you may be taking, and any side effects you may be experiencing.
Follow-Up Visits:
After your participation on this study is complete, you will have follow-up visit every 3 months and you will be asked about your health status. If you do not come to the hospital for a regularly scheduled clinic visit, you will receive a follow-up phone call. The phone call should last about 15 minutes each time.
This is an investigational study. Dasatinib is FDA approved and commercially available for the treatment of certain types of leukemia. The use of dasatinib to treat acral lentiginous melanoma, mucosal melanoma, or chronic sun-damaged melanoma is investigational.
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
DasatinibDrug
Also called BMS-354825, Sprycel
100 mg daily.
Surgical ResectionProcedure or surgery
Complete surgical resection of tumor(s).
| Study group | Role | What they receive |
|---|---|---|
| Group 1: Completely Resectable | Active comparator | Dasatinib 100 mg daily for 7 days and then surgical resection on Day 8. Afterwards, Dasatinib 100 mg daily will be administered for a total of 12 months/12 cycles (1 cycle = 4 weeks of treatment). Receives: Drug: Dasatinib; Procedure: Surgical Resection |
| Group 2: Unresectable | Active comparator | 100 mg Dasatinib daily continued up to 12 months/12 cycles (1 cycle = 4 weeks of treatment). Receives: Drug: Dasatinib |
What is being measured
The primary outcome is the main question the study is designed to answer.
Biologic Response Evaluation of Tumors With and Without Resectable Tumors
Biologic response defined as either (complete or partial) metabolic tumor response after 7 days dasatinib treatment by positron emission tomography (PET) scan, >/= 25% decrease in Fluorodeoxyglucose (FDG) activity on PET without >15% increase in tumoral Ki-67 expression or >/=25% decrease in tumoral Ki-67 expression without >15% increase in FDG activity on PET scan. Complete Metabolic Response (CMR): FDG-avidity all lesions reduced to background FDG-avidity level. Partial Metabolic Response (PMR): >/=25% decrease in FDG-avidity as represented by change in mean Standardized Uptake Values (SUV) max. SUVmax measured by drawing region of interest slightly outside each lesion corresponding to those on CT image \& adjusted for body weight. Measureable disease by PET scan defined as lesions that can be determined to have FDG-avidity of SUVmax of 3 and 2 x background.
PR or CR confirmatory disease assessment performed >4 weeks (28 days) after criteria for response first met.
Measured: Assessment at 7 Days with confirmatory disease assessment performed no less than 4 weeks (28 days) afterwards
Secondary outcomes (1)
Progression-Free Survival
Progression-Free Survival (PFS) is defined as the duration of time from start of treatment to date of first evidence of progression or the date of last follow-up for patients who do not progress.
Measured: Evaluated every 2 cycles (8 weeks) until disease progression or last follow-up, up to two years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Mar 2010 (estimated)
- Study startMar 2011
- Primary completionAug 2014
- Study completionAug 2014
Why it stopped: Slow accrual.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for MelanomaStudies of the same condition, open and under way.
- More trials run by M.D. Anderson Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 19 participants (actual)
Sponsor and investigators
- Lead sponsor
- M.D. Anderson Cancer Center
- Sponsor type
- University, hospital or other
- Collaborators
- Bristol-Myers Squibb
- Responsible party
- Sponsor
- Investigators
- Kevin B. Kim, MD, BA, Study chair, UT MD Anderson Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01092728
- Sponsor's protocol ID
- 2009-0447
- Other IDs
- NCI-2011-00468
- Status last verified
- Jul 2016
- First submitted
- 23 Mar 2010
- Last updated
- 5 Sep 2016
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 5 Sep 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase II Study of Biological Response to Dasatinib Treatment in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma
- ClinicalTrials.gov ID
- NCT01092728
- Acronym / sponsor ID
- 2009-0447
- Conditions
- Melanoma
- Keywords
- Acral lentiginous melanoma, Mucosal melanoma, Chronic sun-damaged melanoma, Surgically removed tumor, biopsied, Sprycel, Dasatinib
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Slow accrual.
- Enrolment
- 19 participants (actual)
- Lead sponsor
- M.D. Anderson Cancer CenterUniversity, hospital or other
- Collaborators
- Bristol-Myers Squibb
- Study start
- Mar 2011
- Primary completion
- Aug 2014 (actual)
- Study completion
- Aug 2014 (actual)
- First posted
- 25 Mar 2010 (estimated)
- Results
- Posted 5 Sep 2016
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical research study is to compare how the drug Sprycel (dasatinib) can help to control the tumor in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma. The safety of this drug will also be studied.
Objectives:
Primary Objectives:
- To compare the biological response of tumors With and Without Resectable Tumors from patients with acral, or mucosal melanomas after treatment with dasatinib.
Secondary Objectives:
- To assess the safety and tolerability of dasatinib in this patient population Completely Resectable Acral, Chronic Sun-damaged (CSD), and Mucosal Melanoma:
- To assess the median time to recurrence and overall survival of patients with completely resectable acral, CSD, and mucosal melanoma treated with dasatinib
- To assess whether FDG-avidity and KIT phosphorylation responses after treatment with dasatinib predicts prolonged time to recurrence and/or overall survival in patients with completely resectable acral, CSD, and mucosal melanomas Not Completely Resectable Acral, CSD, and Mucosal Melanoma:
- To assess the response rate, progression free survival, and overall survival of patients with acral, CSD, and mucosal melanoma treated with dasatinib
- To assess whether FDG-avidity and KIT phosphorylation responses after treatment with dasatinib predicts response rate, progression free survival, and/or overall survival in patients with acral, CSD, and mucosal melanomas
Detailed description
The Study Drug:
Dasatinib is designed to change the function of genes. By changing the function of these genes, it may prevent cancer from growing and spreading.
Study Groups:
If you are found to be eligible to take part in this study, you will be placed into one of two groups depending on if the disease can be removed by surgery on or not. Group 1 will be patients who have melanoma that can be removed by surgery. Group 2 will be patients who have melanoma that cannot be completely removed by surgery.
Study Drug Administration:
For this study, every 4 weeks is a study "cycle."
Dasatinib pills will be taken by mouth with a full glass (8 ounces) of water with or without a meal. The pills should not be crushed or cut, they should be swallowed whole.
If you are in Group 1, you will take 2 dasatinib pills 1 time every day, for 7 days before your already-scheduled surgery. About 6 weeks after surgery (depending on how long it takes you to recover) you will begin taking 2 dasatinib pills 1 time every day for up to 13 cycles as long as you tolerate it and the disease does not come back.
If you are in Group 2, you will take 2 dasatinib pills 1 time every day, for 7 days before your already-scheduled biopsy on Day 8 (+/1 business day) of Cycle 1. Within 5 days after the biopsy, you will begin taking 2 dasatinib pills 1 time every day for up to 13 cycles, as long as you tolerate it and the disease does not come back.
Both groups will be given a pill chart to fill out at home to record when you take the study drug, and how many pills you take each time. You will need to bring the pill chart to every study visit for the study doctor to review. You will also need to bring the pill bottles to each study visit.
Group 1 Study Visits:
After the screening tests have been complete, and before you start taking the study drug, the following procedures will be performed:
- Your weight and vital signs will be measured.
- You will be asked about any drugs you may be taking.
- Your performance status will be recorded.
After 7 days of taking the study drug, and before surgery, the following procedures will be performed:
- You will have a physical exam, including a measurement of your weight and vital signs.
- Blood (about 1 tablespoon) will be drawn for routine tests.
- Your performance status will be recorded.
- You will be asked about any other drugs you may be taking.
- You will have an ECG to check your heart function.
- You will have a PET scan to check the status of the disease.
About 6 weeks after surgery, when you begin taking the study drug on Cycle 1, the following tests and procedures will be performed on Day 1 of each cycle:
- Blood (about 1 tablespoon) will be drawn for routine tests.
- You will have a physical exam, including a measurement of your weight and vital signs.
- Your performance status will be recorded.
- You will be asked about any other drugs you may be taking, and any side effects you may be experiencing.
On Day 15 of Cycle 1 only, the following tests and procedures will be performed:
- Blood (about 1 tablespoon) will be drawn for routine tests.
- You will have a physical exam, including a measurement of your weight and vital signs.
- Your performance status will be recorded.
- You will be asked about any other drugs you may be taking, and any side effects you may be experiencing.
Every 12 weeks while you are receiving treatment, the following tests and procedures will be performed:
- An ECG will be performed to check your heart function.
- You will have a CT scan or MRI scan of the chest, abdomen, and pelvis to check the status of the disease.
Group 2 Study Visits:
After the screening tests have been complete, and before you start taking the study drug, the following procedures will be performed:
- You will have a measurement of your vital signs including your weight.
- You will be asked about any drugs you may be taking.
- Your performance status will be recorded.
After 7 days of taking the study drug, and before the biopsy, the following procedures will be performed:
- You will have a physical exam, including a measurement of your weight and vital signs.
- Blood (about 1 tablespoon) will be drawn for routine tests.
- Your performance status will be recorded.
- You will be asked about any other drugs you may be taking.
- You will have an ECG to check your heart function.
- You will have a PET scan to check the status of the disease.
About 5 days after the biopsy, you will begin taking the study drug again for 3 more weeks to complete Cycle 1. On Day 15 of Cycle 1 only, the following tests and procedures will be performed:
- Blood (about 1 tablespoon) will be drawn for routine tests.
- You will have a physical exam including a measurement of your weight and vital signs.
- Your performance status will be recorded.
- You will be asked about any other drugs you may be taking, and any side effects you may be experiencing.
The following tests and procedures will be performed on Day 1 of each cycle starting with Cycle 2:
- Blood (about 1 tablespoon) will be drawn for routine tests.
- You will have a physical exam, including a measurement of your weight and vital signs.
- Your performance status will be recorded.
- You will be asked about any other drugs you may be taking, and any side effects you may be experiencing.
Every 12 weeks while you are receiving treatment, the following tests and procedures will be performed:
- An ECG will be performed to check your heart function.
- You will have a CT scan or MRI scan of the chest, abdomen, and pelvis to check on the status of the disease.
Length of Study:
You will continue to take the study drug for up to 13 cycles. You will be taken off study early if you experience intolerable side effects, the disease returns (Group 1 only), the disease gets worse (Group 2 only), or if the study doctor thinks it is in your best interest.
If you are in Group 2, and you are benefiting from the treatment, you may be allowed to continue to receive treatment with the study drug after you have completed the 12 study cycles. The study doctor will discuss this option with you in more detail.
End-of-Study Visit:
Within 30 days after the last dose of study drug, you will have an end-of-study visit, at which the following tests and procedures will be performed:
- Blood (about 1 tablespoon) will be drawn for routine tests.
- An ECG will be performed to check your heart function.
- You will have a CT scan or MRI scan of your chest, abdomen, and pelvis performed to check the status of the disease.
- You will have a physical exam, including a measurement of your weight and vital signs.
- Your performance status will be recorded.
- You will be asked about any other drugs you may be taking, and any side effects you may be experiencing.
Follow-Up Visits:
After your participation on this study is complete, you will have follow-up visit every 3 months and you will be asked about your health status. If you do not come to the hospital for a regularly scheduled clinic visit, you will receive a follow-up phone call. The phone call should last about 15 minutes each time.
This is an investigational study. Dasatinib is FDA approved and commercially available for the treatment of certain types of leukemia. The use of dasatinib to treat acral lentiginous melanoma, mucosal melanoma, or chronic sun-damaged melanoma is investigational.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group 1: Completely Resectable | Active comparator | Drug: Dasatinib, Procedure: Surgical ResectionDasatinib 100 mg daily for 7 days and then surgical resection on Day 8. Afterwards, Dasatinib 100 mg daily will be administered for a total of 12 months/12 cycles (1 cycle = 4 weeks of treatment). |
| Group 2: Unresectable | Active comparator | Drug: Dasatinib100 mg Dasatinib daily continued up to 12 months/12 cycles (1 cycle = 4 weeks of treatment). |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (12 listed)
- Patients must have primary, recurrent or metastatic melanoma with one of the following pathology or characteristics: i) acral lentiginous melanoma ii) mucosal melanoma iii) any known KIT mutation.
- (Continued 1) If 20 patients without tumors harboring exon 11 or 13 KIT mutation are enrolled and treated before the completion of the patient accrual of 30, only those with tumors harboring exon 11 or 13 KIT mutation will be enrolled. Likewise, if 10 patients with tumors harboring exon 11 or 13 KIT mutation are enrolled and treated before the completion of the patient accrual of 30, only those without tumors harboring exon 11 or 13 KIT mutation will then be enrolled.
- Patients must have measurable disease by 18-Fluoro-deoxyglucose positron emission tomography (FDG-PET) (with or without computed tomography (CT)) defined as having a maximum standardized uptake value (SUVmax) of 3 and SUVmax ofat least 2 fold greater than background.
- Patients scheduled for FDG-PET should have uptake of the tracer in at least one lesion (tumor-to-muscle ratio >2) in the baseline PET/CT scan in order to be eligible for the follow-up FDG PET scans.
- Patient must have surgically resectable melanoma lesion(s) or biopsiable lesion(s) which are amenable to 2 separate biopsy procedures by a core needle or excision.
Key exclusion criteria (10 listed)
- No other malignancy which required radiotherapy or systemic treatment within the past 5 years.
- Concurrent medical condition which may increase the risk of toxicity, including: a. Pleural or pericardial effusion of any grade.
- Cardiac Symptoms; any of the following should be considered for exclusion: a. Uncontrolled angina, congestive heart failure or MI within (6 months), b. Diagnosed congenital long QT syndrome, c. Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de pointes), d. Prolonged corrected QT interval (QTc) interval on pre-entry electrocardiogram (> 480 msec) [or > 500 msec for patients with a bundle branch block]), e. Subjects with hypokalemia or hypomagnesemia if it cannot be corrected prior to dasatinib administration.
- History of significant bleeding disorder unrelated to cancer, including: a. Diagnosed congenital bleeding disorders (e.g., von Willebrand's disease), b. Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies), c. Ongoing or recent (</= 3 months) significant gastrointestinal bleeding.
- Concomitant Medications, any of the following should be considered for exclusion: a. Category I drugs that are generally accepted to have a risk of causing Torsades de Pointes including: (Patients must discontinue drug 7 days prior to starting dasatinib), I. quinidine, procainamide, disopyramide, II. amiodarone, sotalol, ibutilide, dofetilide, III. erythromycin, clarithromycin, IV. chlorpromazine, haloperidol, mesoridazine, thioridazine, pimozide V. cisapride, bepridil, droperidol, methadone, arsenic, chloroquine, domperidone, halofantrine, levomethadyl, pentamidine, sparfloxacin, lidoflazine.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| DasatinibAlso: BMS-354825, Sprycel100 mg daily. | Drug | Group 1: Completely Resectable, Group 2: Unresectable |
| Surgical ResectionComplete surgical resection of tumor(s). | Procedure or surgery | Group 1: Completely Resectable |
Primary outcome
Biologic Response Evaluation of Tumors With and Without Resectable Tumors
Time frame: Assessment at 7 Days with confirmatory disease assessment performed no less than 4 weeks (28 days) afterwards
Biologic response defined as either (complete or partial) metabolic tumor response after 7 days dasatinib treatment by positron emission tomography (PET) scan, >/= 25% decrease in Fluorodeoxyglucose (FDG) activity on PET without >15% increase in tumoral Ki-67 expression or >/=25% decrease in tumoral Ki-67 expression without >15% increase in FDG activity on PET scan. Complete Metabolic Response (CMR): FDG-avidity all lesions reduced to background FDG-avidity level. Partial Metabolic Response (PMR): >/=25% decrease in FDG-avidity as represented by change in mean Standardized Uptake Values (SUV) max. SUVmax measured by drawing region of interest slightly outside each lesion corresponding to those on CT image \& adjusted for body weight. Measureable disease by PET scan defined as lesions that can be determined to have FDG-avidity of SUVmax of 3 and 2 x background. PR or CR confirmatory disease assessment performed >4 weeks (28 days) after criteria for response first met.
1 secondary outcome
Progression-Free Survival
Time frame: Evaluated every 2 cycles (8 weeks) until disease progression or last follow-up, up to two years
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Sep 2016.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- University of Texas MD Anderson Cancer Center WebsiteLink provided by the sponsor.
Related trials for Melanoma
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingPhase 1
IL-17 Blockade to Decrease irAEs (REPLAY)
Metastatic Melanoma
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
RecruitingPhase 1
A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy
Melanoma
Active, not recruitingPhase 1/2
A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma
Melanoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Kevin B. Kim, MD, BA study chair
UT MD Anderson Cancer Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Dasatinib and Surgical Resection in people with Melanoma, run by M.D. Anderson Cancer Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 12 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 5 Sep 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 5 Sep 2016). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Biologic Response Evaluation of Tumors With and Without Resectable Tumors (time frame: Assessment at 7 Days with confirmatory disease assessment performed no less than 4 weeks (28 days) afterwards). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Sep 2016.